Navigation Links
SignalRX Pharmaceuticals Issued U.S. Patent Covering Novel Kinase Inhibitors For Treating Cancer and Other Diseases
Date:11/12/2013

SAN DIEGO, Nov. 12, 2013 /PRNewswire-iReach/ -- SignalRX Pharmaceuticals Inc., focused on developing more effective oncology drugs through molecular design imparting multiple target inhibition, today announced the issuance of U.S. Patent No. 8,557,807 entitled "Thienopyranones as kinase inhibitors" by the U.S. Patent and Trademark Office claiming composition of matter for a broad generic molecular scaffold (TP) of compounds that possess novel kinase inhibition profiles aimed at imparting maximum anticancer efficacy.  This U.S. patent grants coverage of the TP scaffold compounds into the year 2029 and is complemented by additional U.S. applications as well as by corresponding patent applications pending in other major markets throughout the world. 

The compounds covered in the patent inhibit PI3 kinase and several other key cancer target kinases such as mTORC1, mTORC2, DNA-PK, PLK1 and PIM1.  Further mechanisms of action include induction of oxidative stress and demonstrated anti-cancer stem cell activity.   Furthermore, certain of these compounds can be molecularly manipulated to maintain their PI3 kinase inhibitory activity while simultaneously also inhibiting certain other key cancer targets providing dual inhibition from a single molecule, in line with the CRIMP (Control Resulting from Inhibition of Multiple Pathways) platform which is focused on the development of more effective cancer treatments.  Additionally, other diseases besides cancer such as, age-related macular degeneration and autoimmune diseases along with various inflammatory diseases all potentially can be treated by the kinase inhibition properties of these compounds.

"This patent is a key member of our growing intellectual property portfolio as it provides protection for the cutting edge efforts to deliberately design molecules having multiple mechanisms of action to overcome the devastating ability of cancer cells to shrug
'/>"/>

SOURCE SignalRx Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Sales Horizons, a leader in ... sales training course – Mastering the Complex Sale ... , Drawn from proven sales training programs used by ... Complex Sale online sales training course is available to ... face-to-face contact with customers, like technical support, engineers, clinical ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... SAN and NYSE: SNY) today announced that the Companies ... (FDA) rare pediatric disease priority review voucher in connection ...  The priority review voucher entitles the holder to designate ... expedited 6-month review from the filing date instead of ...
(Date:7/30/2014)... BURLINGTON, Mass. , July 30, 2014 /PRNewswire/ ... surveyed pharmacy and medical directors in ... key drivers of biosimilar market penetration will be ... care organizations (MCOs) and the expected lower cost ... strategies for biosimilars that meet their pricing expectations ...
(Date:7/30/2014)... -- The Chicago Bears are excited to announce the team,s ... an effort to raise awareness of skin cancer. Through ... me™ skin cancer screenings at a preseason fan event ... SPOT me™ is an educational campaign designed to inform the ... skin cancer, and encourages people to get screened by ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4
... 20 PreViser Corporation,( http://www.previser.com ), a Washington ... technology to the dental profession,announced today the finalization ... Ltd ( http://www.previser.co.uk ) of Birmingham, England to,market ... and the,Republic of Ireland., OHI Ltd is ...
... living computers by genetically altering bacteria. The findings of ... of Biological Engineering, demonstrate that computing in living cells ... applications including data storage and as a tool for ... from the biology and the mathematics departments of Davidson ...
... May 19 Amarin Corporation,plc (NASDAQ: AMRN ) ... quarter and full year ended December 31, 2007. For ... of $7.9 million, or,$0.72 per share, compared with a ... the fourth quarter of 2006. The increase in net ...
Cached Biology Technology:PreViser and Oral Health Innovations Ltd Form UK Partnership to Provide Oral Health Scoring and Risk Analysis 2Researchers bring new meaning to the term 'computer bug' 2Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 2Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 3Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 4Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 5Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 6Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 7Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 8Amarin Announces Financial Results for Fourth Quarter and Full Year 2007 9
(Date:7/30/2014)... Progress in developing robust therapies for spinal cord injury ... has been slow. A great deal has been learned ... factors and the environmental factors that regulate axon growth, ... resulted in clinically available therapeutics. Prof. Lemmon and his ... therapeutic bottleneck has many root causes, but a consensus ...
(Date:7/30/2014)... the roughly 3,000 pieces is still in its infant ... will be of major significance. "Amazingly often, we are ... Fushun amber that we found in Baltic amber," explained ... Baltic amber comes from the Baltic Sea region, which ... finds are, e.g., the coastal regions of Mecklenburg, Poland ...
(Date:7/30/2014)... map of the carbon stocks stored on land ... and improved methodology used to make the map ... economies. The new carbon map also reveals ... the critical input to studies of deforestation and ... purposes. The technique includes the determination of uncertainty ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... birth of eminent biologist today (Thursday) Charles Darwin a ... and protect Northern Ireland,s natural heritage. Queen,s University ... teamed up to form the Natural Heritage Research Partnership ... tendering. The project is being led by Quercus, ...
... Explorer SMOS satellite can take place between July and October ... Space are now making detailed preparations for the last crucial ... The Soil Moisture and Ocean Salinity (SMOS) satellite has been ... since May last year awaiting for a third stage of ...
... in German . The use of uranium ... that people may come into contact with it, and the ... However, radioactivity is not the only problem related to contact ... dangerous to human health. Researchers are still looking for simple, ...
Cached Biology News:Darwin anniversary heralds new conservation research era for Northern Ireland 2ESA's water mission on track for launch 2A pocketful of uranium 2
... Translation System is ideal for both radioactive ... Translation System: Provides five pre-mixed nucleotide ... Yields >10 8 cpm/g control ... to monitor the performance of the system ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
... Direct SPA Screening Assay, 5 ... that eliminate lengthy sample extraction procedures ... use).Range: 1.32-84.28 ng/ml (4-256 pmol/ml).Sensitivity: 0.65 ... 2-8 C. Category: Drug Screening & ...
Biology Products: